Articles from NorthStar Medical Technologies, LLC

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, LLC (NorthStar), a global radiopharmaceutical supply-chain partner, today announced a long-term strategic partnership through which NorthStar will produce Copper-67 (Cu-67) and provide comprehensive radiopharmaceutical manufacturing services to support NUCLIDIUM's therapeutic programs from clinical development through commercialization. Copper-67 is the therapeutic isotope component of NUCLIDIUM’s radiotheranostic programs to treat cancers with high unmet medical need.

NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a strategic partnership with Quarkmed, a Beijing-based contract research organization (CRO) specializing in nuclear medicine and radiopharmaceutical clinical development, with expertise spanning pharmaceutical regulatory affairs, clinical development, and clinical trial operations. Quarkmed will serve as NorthStar’s Registration Agent in China, enabling pharmaceutical and biotechnology companies worldwide to use NorthStar’s n.c.a. Ac-225 in Investigational New Drug (IND) applications submitted to China’s Center for Drug Evaluation (CDE).

NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a multi-year growth capital facility of up to $185 million with Hercules Capital, Inc. (NYSE: HTGC) to support NorthStar’s continued growth and expansion. The financing, including $100 million upfront, will accelerate investment in isotope production and in clinical and commercial drug manufacturing capabilities, enabling NorthStar’s pharmaceutical and biotechnology partners to advance next-generation precision cancer therapies to patients worldwide.

NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Mr. Jon Coulter as Non-Executive Chairman. Mr Coulter has been a Board Member of NorthStar since 2010 and was appointed to the post effective March 26, 2025. He succeeds Mr. Stephen Merrick, who joined NorthStar in 2016, has served as Executive Chairman since July 2023 and is now retiring from that position.

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive.

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive.

NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., as its new President and Chief Executive Officer (CEO) effective Monday, June 26, 2023. Dr. Scholz joined NorthStar in 2021, and was promoted to President and Chief Operating Officer (COO) in 2022. Mr. Stephen Merrick, who joined NorthStar in 2016 and has been CEO since 2018, will assume the role of Executive Chairman. The changes reflect NorthStar’s long-term strategy for continued growth and corporate development.

NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of one of its key executives. The announcement comes as NorthStar reaches a pivotal stage in its growth and industry influence. Dr. Frank Scholz has been named President and Chief Operating Officer of NorthStar. He now holds oversight of Corporate Development, External Affairs, Sales, Marketing and Public Relations in addition to his current responsibilities for Program Management, Regulatory Affairs, Engineering & Technology, Manufacturing Operations & Supply Chain, and Advanced Radioisotope & Therapeutic Technologies. He will continue to report to Chief Executive Officer Stephen Merrick.

NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer. In this new position, he brings more than 20 years of relevant operational experience in the pharmaceutical and life sciences industries to the Company. Dr. Scholz will report to President and Chief Executive Officer Stephen Merrick.